Cell Therapy

News

Bayer boosts cell therapy pipeline with BlueRock acquisition

Bayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes a treatment for Parkinson’s disease.

Views & Analysis

Finding the right reimbursement model for gene therapies

With cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, vice president of Kantar’s Health division, to learn how the industry can overcome fu

News

Former Alexion CEO Hallal makes comeback at cell therapy hol...

Massachusetts holding company ElevateBio has launched with $150m in initial funding from a range of investors on a mission to build a portfolio of cell and gene therapy companies.<

News

Mesoblast poised to file cell therapy for GVHD in US

Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA.

News

Cell Mogrify gets £420k funding for regenerative cell therap...

UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes.

R&D

Will cell and gene therapies disrupt reimbursement?

Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people with rare diseases and cancers – but they could also mean healthcare systems

Bayer boosts cell therapy pipeline with BlueRock acquisition

Finding the right reimbursement model for gene therapies

Former Alexion CEO Hallal makes comeback at cell therapy hol...

Mesoblast poised to file cell therapy for GVHD in US

Cell Mogrify gets £420k funding for regenerative cell therap...

Will cell and gene therapies disrupt reimbursement?

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

Cell Therapy

Editor's Picks